Back to top
more

Align Technology (ALGN)

(Real Time Quote from BATS)

$140.68 USD

140.68
815,024

+2.91 (2.11%)

Updated Aug 5, 2025 01:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

Kevin Cook headshot

Stock-Picking is a Cult

by Kevin Cook

A plea to Millennials to learn the greatest, most fascinating game on the planet.

    Zacks Equity Research

    Abbott (ABT) Q2 Earnings & Revenues Top Estimates, View Up

    by Zacks Equity Research

    Abbott (ABT) posts another quarter of strong EPD and Medical Devices performance. Particularly, Abbott has been riding high on a healthy growth within its Diabetes Care business.

      Tracey Ryniec headshot

      A How-To Plan for Picking Stocks

      by Tracey Ryniec

      Confused about how you should start investing in stocks? Kevin Cook and Tracey Ryniec give you their best stock picking tips and secrets.

        Zacks Equity Research

        Haemonetics Gains on Strong Plasma, Wider Global Footprint

        by Zacks Equity Research

        Strong growth of Haemonetics' (HAE) plasma-derived biopharmaceuticals is attributable to solid end-market demand.

          Zacks Equity Research

          What's in the Cards for Zimmer Biomet (ZBH) in Q2 Earnings?

          by Zacks Equity Research

          Focusing on the thrust areas like quality correction, supply recovery efforts and product introductions, Zimmer Biomet (ZBH) is expected to retain robust top-line numbers within its S.E.T. arm.

            Zacks Equity Research

            Can Overall Growth Drive Align Technology (ALGN) Q2 Earnings?

            by Zacks Equity Research

            Align Technology (ALGN) likely to gain from strength in Invisalign space as well as Scanner and Service business in Q2.

              Zacks Equity Research

              Danaher (DHR) to Report Q2 Earnings: What's in the Cards?

              by Zacks Equity Research

              Danaher's (DHR) Q2 earnings will likely reflect negative impact of Dental segment's prevalent supply-chain issues and rising cost. However, benefits of DBS implementation might turn things in favor.

                Zacks Equity Research

                Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?

                by Zacks Equity Research

                Thermo Fisher (TMO) continues with its impressive performance momentum across analytical instrument businesses witnessing escalating global demand.

                  Zacks Equity Research

                  Can Strategic Alliances Aid LabCorp's (LH) Q2 Earnings?

                  by Zacks Equity Research

                  LabCorp (LH) is expected to gain traction from a solid LabCorp Diagnostics segment in Q2, courtesy of a favorable price, mix, tuck-in acquisitions and organic volume.

                    Zacks Equity Research

                    Can Rhythm and Neuro Aid Boston Scientific (BSX) Q2 Earnings?

                    by Zacks Equity Research

                    Boston Scientific (BSX) set to ride high on strength in Rhythm and Neuro business in Q2.

                      Zacks Equity Research

                      QIAGEN Test-Menu Expansion on Track, Low HPV Sales a Woe

                      by Zacks Equity Research

                      QIAGEN's (QGEN) HPV sales in the United States remain tepid. Weak APAC sales are due to bleak applied testing business.

                        Sreyoshi Mukherjee headshot

                        Trump's APAC Focus Puts Spotlight on These 3 MedTech Stocks

                        by Sreyoshi Mukherjee

                        Despite the trade war upheaval in Asia, some medical device companies stand strong in the APAC region.

                          Zacks Equity Research

                          Here's Why You Should Add Edwards Lifesciences (EW) Now

                          by Zacks Equity Research

                          We are upbeat about Edwards Lifesciences' (EW) strong transcatheter valve sales in the domestic market as well as overseas.

                            Zacks Equity Research

                            Here's Why You Should Invest in BioScrip (BIOS) Right Now

                            by Zacks Equity Research

                            We are upbeat about BioScrip's (BIOS) progress in the last reported quarter, courtesy of its multi-faceted CORE plan to improve financial position.

                              Zacks Equity Research

                              Zacks.com highlights: Deckers Outdoor, WellCare Health Plans, Align Technology, Capstone Turbine and Twitter

                              by Zacks Equity Research

                              Zacks.com highlights: Deckers Outdoor, WellCare Health Plans, Align Technology, Capstone Turbine and Twitter

                                Zacks Equity Research

                                Can Medical Devices Strength Drive Abbott (ABT) Q2 Earnings?

                                by Zacks Equity Research

                                Abbott (ABT) poised to gain on continued growth in Medical Devices business in Q2.

                                  Sanghamitra Saha headshot

                                  5 Stocks to Enjoy Earnings Beat Before Q2 Release

                                  by Sanghamitra Saha

                                  These top-ranked stocks are likely to beat on the bottom line in their next releases.

                                    Zacks Equity Research

                                    Why You Should Add Boston Scientific (BSX) to Your Portfolio

                                    by Zacks Equity Research

                                    Boston Scientific's (BSX) agreement for Cryterion Medical buyout in the field of atrial fibrillation buoys investor optimism on the stock.

                                      Zacks Equity Research

                                      Abaxis (ABAX) and Zoetis Merger Deal Crosses HRS Hurdle

                                      by Zacks Equity Research

                                      With the adoption of Abaxis' (ABAX) point-of-care diagnostic instruments post acquisition, the combined entity's veterinary diagnostics category should grow faster than the animal health industry.

                                        Zacks Equity Research

                                        Medtronic (MDT) Rides on Innovation, Rising Costs a Woe

                                        by Zacks Equity Research

                                        Medtronic (MDT) continues to meaningfully accelerate all its three fundamental growth strategies, namely therapy innovation, globalization and economic value.

                                          Zacks Equity Research

                                          Boston Scientific to Buy Cryterion Medical to Widen EP Suite

                                          by Zacks Equity Research

                                          Boston Scientific (BSX) forges ahead with initiatives to strengthen its hold in the high-potential EP market.

                                            Zacks Equity Research

                                            Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio

                                            by Zacks Equity Research

                                            We are upbeat about Bio-Rad's (BIO) solid growth in geographies like North America, China and Asia Pacific.

                                              Zacks Equity Research

                                              Insulet Banks on Omnipod's Growing Market Reach, Runs Risks

                                              by Zacks Equity Research

                                              We are upbeat about the solid uptake of Insulet's (PODD) Omnipod System in the United States and other geographies.

                                                Zacks Equity Research

                                                Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?

                                                by Zacks Equity Research

                                                Is (ALGN) Outperforming Other Medical Stocks This Year?

                                                  Zacks Equity Research

                                                  Here's Why You Should Invest in Align Technology (ALGN) Now

                                                  by Zacks Equity Research

                                                  We are upbeat about Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally, particularly in the Asia-Pacific and EMEA regions.